1. Home
  2. KPTI vs SQNS Comparison

KPTI vs SQNS Comparison

Compare KPTI & SQNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • SQNS
  • Stock Information
  • Founded
  • KPTI 2008
  • SQNS 2003
  • Country
  • KPTI United States
  • SQNS France
  • Employees
  • KPTI 325
  • SQNS N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • SQNS Semiconductors
  • Sector
  • KPTI Health Care
  • SQNS Technology
  • Exchange
  • KPTI Nasdaq
  • SQNS Nasdaq
  • Market Cap
  • KPTI 81.1M
  • SQNS 85.7M
  • IPO Year
  • KPTI 2013
  • SQNS 2011
  • Fundamental
  • Price
  • KPTI $0.66
  • SQNS $3.19
  • Analyst Decision
  • KPTI Strong Buy
  • SQNS Strong Buy
  • Analyst Count
  • KPTI 4
  • SQNS 1
  • Target Price
  • KPTI $5.00
  • SQNS $7.50
  • AVG Volume (30 Days)
  • KPTI 671.2K
  • SQNS 118.6K
  • Earning Date
  • KPTI 02-27-2025
  • SQNS 02-11-2025
  • Dividend Yield
  • KPTI N/A
  • SQNS N/A
  • EPS Growth
  • KPTI N/A
  • SQNS N/A
  • EPS
  • KPTI N/A
  • SQNS 1.65
  • Revenue
  • KPTI $148,442,000.00
  • SQNS $30,555,000.00
  • Revenue This Year
  • KPTI $5.47
  • SQNS $10.14
  • Revenue Next Year
  • KPTI $6.33
  • SQNS $8.54
  • P/E Ratio
  • KPTI N/A
  • SQNS $1.99
  • Revenue Growth
  • KPTI 1.77
  • SQNS N/A
  • 52 Week Low
  • KPTI $0.58
  • SQNS $0.85
  • 52 Week High
  • KPTI $1.70
  • SQNS $7.43
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • SQNS 50.30
  • Support Level
  • KPTI $0.60
  • SQNS $3.00
  • Resistance Level
  • KPTI $0.70
  • SQNS $3.64
  • Average True Range (ATR)
  • KPTI 0.05
  • SQNS 0.22
  • MACD
  • KPTI -0.00
  • SQNS -0.01
  • Stochastic Oscillator
  • KPTI 46.61
  • SQNS 34.78

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

Share on Social Networks: